The Atlanta Journal-Constitution
GeoVax Labs, Inc., a Smyrna-based biotechnology company that creates and tests HIV/AIDS vaccines, has been granted federal permission to begin a phase 1 clinical trial for a treatment for people infected with HIV.
The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection.
The Phase 1 clinical trial will monitor safety while evaluating the ability of the vaccine to elicit protective immune responses in vaccinated participants.
The trial is based on the achievement of post-vaccine viral control in animal studies conducted in recently infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University.